1-8 of 8
John Byrd
Close
Sort by
Journal Articles

Natural Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation

Don Benson, Leslie Andritsos, Mehdi Hamadani, Thomas Lin, Joseph Flynn, Jeffrey Jones, William Blum, MD, Patrick Elder, Gerard Lozanski, John Byrd, Steven Devine
Journal: Blood
Blood (2008) 112 (11): 3300.
https://doi.org/10.1182/blood.V112.11.3300.3300
Published: 2008
Journal Articles

Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23 + lymphoma cell lines

Nuzhat I. Pathan, Peter Chu, Kandasamy Hariharan, Carolyn Cheney, Arturo Molina, John Byrd
Journal: Blood
Blood (2008) 111 (3): 1594–1602.
https://doi.org/10.1182/blood-2007-03-082024
Published: 2008
Journal Articles

Gene Dosage of the Cell Cycle Regulatory Phosphatases Cdc25C and PP2A Determines Sensitivity to Lenalidomide in del(5q) MDS.

Sheng Wei, MD, Kathy Rocha, BS, Ann Williams, Ph.D., Xianhong Chen, Ph.D, P.K. Burnette, Ph.D., Julie Y. Djeu, Ph.D., Qing Liu, Ph.D., John Byrd, M.D., Lubomir Sokol, M.D., Nick Lawrence, Ph.D., Roberta Pireddu, Ph.D, Gordon Dewald, Ph.D., Jaroslaw Maciejewski, M.D., Alan List, M.D.
Journal: Blood
Blood (2007) 110 (11): 118.
https://doi.org/10.1182/blood.V110.11.118.118
Published: 2007
Journal Articles

Combination Chemoimmunotherapy with Pentostatin, Cyclophosphamide and Rituximab Shows Significant Clinical Activity with Low Accompanying Toxicity in Previously Untreated B-Chronic Lymphocytic Leukemia.

Neil Kay, MD, Susan Geyer, PhD, Timothy Call, MD, Tait Shanafelt, MD, Clive Zent, MD, Diane Jelinek, PhD, Renee Tschumper, Nancy Bone, Gordon Dewald, PhD, Thomas Lin, PhD, Nyla Heerema, PhD, Laura Smith, Michael Grever, MD, John Byrd, MD
Journal: Blood
Blood (2006) 108 (11): 35.
https://doi.org/10.1182/blood.V108.11.35.35
Published: 2006
Journal Articles

Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102).

Wendy Stock, MD, Daohai Yu, PhD, Ben Sanford, MS, Gerard Lozanski, Ph.D, Spero Cataland, MD, Ravi Vij, MD, John Byrd, MD, Bayard Powell, MD, Meir Wetzler, MD, Maher Albitar, MD, Dorie Sher, BS, Colin Edwards, MS, Eva Hoke, BS, Clara D. Bloomfield, MD, Richard A. Larson, MD
Journal: Blood
Blood (2005) 106 (11): 145.
https://doi.org/10.1182/blood.V106.11.145.145
Published: 2005
Journal Articles

Global Assessment of Promoter Methylation in a Murine Model of Cancer Identifies ID4 as a Putative Novel Tumor Suppressor Gene in Human Leukemia.

Li Yu, MD., Chunhui Liu, Jeff Vandeusen, Brian Becknell, Zunyan Dai, Yue-Zhong Wu, Aparna Raval, Te-Hui Liu, Wei Ding, Charlene Mao, Shujun Liu, Laura T. Smith, Stephen Lee, Laura Rassenti, Guido Marcucci, John Byrd, Michael A. Caligiuri, MD., Christoph Plass, PhD.
Journal: Blood
Blood (2004) 104 (11): 3488.
https://doi.org/10.1182/blood.V104.11.3488.3488
Published: 2004
Journal Articles

A Novel Celecoxib Derivative, OSU03012, Induces Cytotoxicity in Primary CLL Cells and Transformed B-Cell Lymphoma Via a Caspase and Bcl-2 Independent Mechanism.

Amy Johnson, PhD, Lisa Smith, Jiuxiang Zhu, Nyla Heerema, PhD, Sara Guster, Andrew Mone, MD, PhD, Michael Grever, MD, Ching-Shih Chen, PhD, John Byrd, MD
Journal: Blood
Blood (2004) 104 (11): 3471.
https://doi.org/10.1182/blood.V104.11.3471.3471
Published: 2004
Journal Articles

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

Clinical Trials & Observations
Michael J. Keating, Ian Flinn, Vinay Jain, Jacques-Louis Binet, Peter Hillmen, John Byrd, Maher Albitar, Lee Brettman, Pedro Santabarbara, Bret Wacker, Kanti R. Rai
Journal: Blood
Blood (2002) 99 (10): 3554–3561.
https://doi.org/10.1182/blood.V99.10.3554
Published: 2002